Prognostic value of positron emission tomography/computed tomography in transplant-eligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET study
暂无分享,去创建一个
P. Sonneveld | M. Béné | P. Moreau | H. Avet-Loiseau | X. Leleu | B. Jamet | C. Bailly | C. Bodet-Milin | F. Kraeber-Bodéré | B. de Keizer | E. Itti | T. Facon | J. Vermeulen | C. D. de Boer | M. Minnema | L. Karlin | A. Perrot | K. Belhadj | C. Hulin | M. Levin | S. Zweegman | D. Caillot | J. Lambert | L. Pei | T. Kampfenkel | Fabio Rigat
[1] P. Sonneveld,et al. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. , 2021, The Lancet. Oncology.
[2] P. Sonneveld,et al. Standardization of 18F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] C. Nanni,et al. Glucose Metabolism Quantified by SUVmax on Baseline FDG-PET/CT Predicts Survival in Newly Diagnosed Multiple Myeloma Patients: Combined Harmonized Analysis of Two Prospective Phase III Trials , 2020, Cancers.
[4] P. Sonneveld,et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study , 2019, The Lancet.
[5] C. Nanni,et al. Interest of Pet Imaging in Multiple Myeloma , 2019, Front. Med..
[6] Hiroki Kobayashi,et al. Low hexokinase-2 expression-associated false-negative 18F-FDG PET/CT as a potential prognostic predictor in patients with multiple myeloma , 2019, European Journal of Nuclear Medicine and Molecular Imaging.
[7] M. Kumar,et al. The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma. , 2018, Blood.
[8] O. Stephens,et al. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing , 2017, Nature Communications.
[9] Jean-Michel Nguyen,et al. Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Caleb K. Stein,et al. Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. , 2017, Blood.
[11] Bart Barlogie,et al. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. , 2017, The Lancet. Oncology.
[12] H. Goldschmidt,et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. , 2016, The Lancet. Oncology.
[13] C. Nanni,et al. Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe) , 2016, European Journal of Nuclear Medicine and Molecular Imaging.
[14] R. Fanin,et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. , 2011, Blood.
[15] B. Barlogie,et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. , 2009, Blood.